Collaboration of breast cancer clinic and genetic counseling division for BRCA1 and BRCA2 mutation family in Japan

被引：5

作者：

Takeda M. ^{[1
]}

Ishida T. ^{[1
]}

Ohnuki K. ^{[1
]}

Suzuki A. ^{[1
]}

Sakayori M. ^{[2
]}

Ishioka C. ^{[2
]}

Nomizu T. ^{[3
]}

Noguchi S. ^{[4
]}

Matsubara Y. ^{[5
]}

Ohuchi N. ^{[1
]}

机构：

[1] Divisions of Surgical Oncology, Tohoku University Graduate School of Medicine, Aobaku, Sendai 980-8574

[2] Divisions of Oncology, Tohoku University Graduate School of Medicine

[3] Division of Surgery, Hoshi General Hospital

[4] Division of Surgical Oncology, Osaka University Graduate School of Medicine

[5] Division of Medical Genetics, Tohoku University Graduate School of Medicine

来源：

Breast Cancer | 2004年 / 11卷 / 1期

关键词：

BRCA1; BRCA2; Familial breast cancer; Hereditary breast cancer;

D O I：

10.1007/BF02967998

中图分类号：

学科分类号：

摘要：

Background: BRCA1 and BRCA2 mutations cause high breast cancer incidence rates as high as 80%. Although prophylactic therapy is still controversial, several prophylactic therapies have been proposed and tried for BRCA1 and BRCA2 mutation carriers. Prophylactic surgery, chemo-prevention and precise screening have been proposed as prophylactic therapy. All BRCA1 and BRCA2 mutation carriers need knowledge about their disease and the countermeasures that are used to protect against onset of disease. Counseling plays an important role in this regard for people with genetic diseases. Therefore, collaboration between breast cancer clinics and genetic counseling services is the most important issue in clinical practice. Our group consists of three national universities and a general hospital. In this article we describe our trial to construct a clinical system against hereditary breast cancer as an interim report for the Japanese Ministry of Health, Labour and Welfare. Patients and Methods: Twenty familial breast cancer patients were registered in this study. The whole sequence of BRCA1 and BRCA2 were analyzed. If pathological mutations were detected, their first degree families were introduced to the counseling division at each institute when candidates visited counseling divisions. Results and Discussion: Four cases of a deleterious mutation in BRCA1 or BRCA2 were detected among 20 cases. Their first degree relatives are now under consideration for visiting counseling divisions. The clinical system described in this study should play a role to protect BRCA1 or BRCA2 mutation carriers in Japan.

引用

页码：30 / 32

页数：2

共 11 条

[1] Lynch H.T., Lynch J.F., Breast cancer genetics in an oncology clinic: 328 Consecutive patients, Cancer Genetics and Cytogenetics, 22, 4, pp. 369-371, (1986)
[2] Ikeda N., Miyoshi Y., Yoneda K., Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families, Int J Cancer, 91, pp. 83-88, (2001)
[3] Noguchi S., Kasugai T., Miki Y., Fukutomi T., Emi M., Nomizu T., Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women, Cancer, 85, 10, pp. 2200-2205, (1999)
[4] Neuhausen S., Gilewsld T., Norton L., Tran T., McGuire P., Swensen J., Hampel H., Borgen P., Brown K., Skolnick M., Shattuck-Eidens D., Jhanwar S., Goldgar D., Offit K., Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer, Nat Genet, 13, pp. 126-128, (1996)
[5] Hartmann L.C., Schaid D.J., Woods J.E., Crotty T.P., Myers J.L., Arnold P.G., Petty P.M., Sellers T.A., Johnson J.L., McDonnell S.K., Frost M.H., Jenkins R.B., Grant C.S., Michels V.V., Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer, New England Journal of Medicine, 340, 2, pp. 77-84, (1999)
[6] Moller P., Borg A., Evans D.G., Haites N., Reis M.M., Vasen H., Anderson E., Steel C.M., Apold J., Goudie D., Howell A., Lalloo F., Maehle L., Gregory H., Heimdal K., Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy, Int J Cancer, 101, pp. 555-559, (2002)
[7] Rebbeck T.R., Lynch H.T., Neuhausen S.L., Narod S.A., Van't Veer L., Garber J.E., Evans G., Isaacs C., Daly M.B., Matloff E., Olopade O.I., Weber B.L., Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations, New England Journal of Medicine, 346, 21, pp. 1616-1622, (2002)
[8] Contant C.M., Menke-Pluijmers M.B., Seynaeve C., Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation, Eur J Surg Onco, 128, pp. 627-632, (2002)
[9] Fisher B., Costantino J.P., Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study, J Natl Cancer Inst, 91, (1999)
[10] Sekine M., Nagata H., Tsuji S., Hirai Y., Fujimoto S., Hatae M., Kobayashi I., Fujii T., Nagata I., Ushijima K., Obata K., Suzuki M., Yoshinaga M., Umesald N., Satoh S., Enomoto T., Motoyama S., Tanaka K., Mutational analysis of ovarian cancer families: Two common founder mutations of BRCA1 in Japanese population, Clin Cancer Res, 7, pp. 3144-3150, (2001)

← 1 2 →